Home › Ovarian Cancer › Texas › Dallas
Ovarian Cancer clinical trials in Dallas, TX
28 studies for Ovarian Cancer are looking for participants at sites in and around Dallas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Dallas
DESTINY-PANTUMOUR04
RecruitingObservational study
- Research Site, Dallas
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- UT Southwestern Medical Center, Dallas
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecruitingPhase 1
- Texas Oncology - DFW (Sammons CC), Dallas
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RecruitingPhase 2
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
- UT Southwestern Medical Center, Dallas
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecruitingPhase 2/3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecruitingPhase 1
- Normunity Investigational Site, Dallas
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
RecruitingPhase 1
- SCRI - Mary Crowley Cancer Research, Dallas
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecruitingPhase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- Texas Oncology, P.A., Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Mary Crowley Cancer Research, Dallas
- Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecruitingPhase 2
- Baylor Scott & White Research Institute, Dallas
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- Texas Oncology - DFW, Dallas
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
- University of Texas Southwestern, Dallas
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RecruitingPhase 1/2
- Texas Oncology, P.A., Dallas
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
Recruiting
- UT Southwestern Parkland Health and Hospital System, Dallas
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RecruitingPhase 1/2
- Next Oncology, Dallas
- UTSW Medical Center, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
RecruitingPhase 1
- Dren Investigational Site, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Dallas
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
RecruitingPhase 1/2
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
RecruitingPhase 1
- Mary Crowley Cancer Research, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
RecruitingPhase 1
- NEXT Oncology, Dallas, Dallas
About Ovarian Cancer
Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.
More about Ovarian Cancer on MedlinePlus
Ovarian Cancer trials in other cities
- Houston, TX89 studies
- New York City, NY69 studies
- Boston, MA61 studies
- Los Angeles, CA50 studies
- Nashville, TN49 studies
- Arlington, VA46 studies
- Philadelphia, PA44 studies
- Columbus, OH39 studies
- St. Louis, MO38 studies
- Chicago, IL36 studies
- San Antonio, TX31 studies
- Cleveland, OH30 studies
Other studies in Dallas
- Breast Cancer55 studies
- Non-Small Cell Lung Cancer52 studies
- Metastatic Cancer42 studies
- Heart Failure42 studies
- Cancer (all types)37 studies
- Prostate Cancer36 studies
- Colorectal Cancer33 studies
- Obesity30 studies
- Bladder Cancer27 studies
- Lung Cancer27 studies
- Endometrial Cancer24 studies
- Cardiovascular Disease23 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.